Claims for Patent: 7,303,746

✉ Email this page to a colleague

Summary for Patent: 7,303,746

Title:	Methods of treating eye disorders with modified chimeric polypeptides
Abstract:	Modified chimeric polypeptides with improved pharmacokinetics are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
Inventor(s):	Wiegand; Stanley J. (Croton on Hudson, NY), Papadopoulos; Nicholas (LaGrangeville, NY), Yancopoulos; George D. (Yorktown Heights, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	10/988,243
Patent Claims:	1. A method of treating retinal neovascularization, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF) to a patient in need thereof, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:16. 2. The method of claim 1, wherein neovascularization is induced by ischemia. 3. A method of treating, ameliorating, or inhibiting choroidal neovascularization, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGE) to a patient in need thereof, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:16. 4. A method of treating, ameliorating, or inhibiting vascular leak in the retina, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF) to a patient in need thereof, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:16. 5. A method of treating, ameliorating, or inhibiting retinal edema, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF) to a patient in need thereof, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:16.

Details for Patent 7,303,746

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011	⤷ Start Trial	2024-11-12
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	August 16, 2018	⤷ Start Trial	2024-11-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,303,746

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Africa	200600157	⤷ Start Trial
South Africa	200110068	⤷ Start Trial
Yugoslavia	86901	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2005000895	⤷ Start Trial
World Intellectual Property Organization (WIPO)	02060489	⤷ Start Trial
World Intellectual Property Organization (WIPO)	0075319	⤷ Start Trial
Uruguay	28396	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.